A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
NCT04936529
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neuroblastoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- Any age
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- September 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.